Exploratory Studies with NX-13: Oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1

Nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) is an emerging therapeutic target for a spectrum of human diseases. NX-13 is a small molecule therapeutic designed to target and activate NLRX1 to induce immunometabolic changes resulting in lower inflammation and t...

Full description

Saved in:
Bibliographic Details
Published in:Drug Chem Toxicol
Main Authors: Leber, Andrew, Hontecillas, Raquel, Zoccoli-Rodriguez, Victoria, Ehrich, Marion, Chauhan, Jyoti, Bassaganya-Riera, Josep
Format: Artigo
Language:Inglês
Published: 2022
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7182494/
https://ncbi.nlm.nih.gov/pubmed/31650868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/01480545.2019.1679828
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items